

Edna GrÃ¼nblatt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1679728/publications.pdf>

Version: 2024-02-01

193
papers

11,014
citations

41258

49
h-index

39575

94
g-index

206
all docs

206
docs citations

206
times ranked

16264
citing authors

#	ARTICLE	IF	CITATIONS
1	An overview of the first 5 years of the ENIGMA obsessive-compulsive disorder working group: The power of worldwide collaboration. <i>Human Brain Mapping</i> , 2022, 43, 23-36.	1.9	51
2	Problematic use of the internet during the COVID-19 pandemic: Good practices and mental health recommendations. <i>Comprehensive Psychiatry</i> , 2022, 112, 152279.	1.5	52
3	Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 886-895.	2.3	70
4	Media use and emotional distress under COVID-19 lockdown in a clinical sample referred for internalizing disorders: A Swiss adolescents' perspective. <i>Journal of Psychiatric Research</i> , 2022, 147, 313-323.	1.5	7
5	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	9.4	700
6	Brain-derived neurotrophic factor protects serotonergic neurons against 3,4-methylenedioxymethamphetamine (Ecstasy) induced cytoskeletal damage. <i>Journal of Neural Transmission</i> , 2022, 129, 703-711.	1.4	5
7	Promising Developments in the Use of Induced Pluripotent Stem Cells in Research of ADHD. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , .	0.8	1
8	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 652.	4.5	31
9	A review of the genetic basis of problematic Internet use. <i>Current Opinion in Behavioral Sciences</i> , 2022, 46, 101149.	2.0	9
10	Genetics of OCD and Related Disorders; Searching for Shared Factors. <i>Current Topics in Behavioral Neurosciences</i> , 2021, 49, 1-16.	0.8	6
11	Genome-wide association study of pediatric obsessive-compulsive traits: shared genetic risk between traits and disorder. <i>Translational Psychiatry</i> , 2021, 11, 91.	2.4	23
12	The Interplay Between Postsynaptic Striatal D2/3 Receptor Availability, Adversity Exposure and Odd Beliefs: A [11C]-Raclopride PET Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 1495-1508.	2.3	3
13	Generation of integration-free induced pluripotent stem cell lines from four pediatric ADHD patients. <i>Stem Cell Research</i> , 2021, 53, 102268.	0.3	7
14	Generation of integration-free induced pluripotent stem cells from healthy individuals. <i>Stem Cell Research</i> , 2021, 53, 102269.	0.3	6
15	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	5.8	140
16	Media use before, during and after COVID-19 lockdown according to parents in a clinically referred sample in child and adolescent psychiatry: Results of an online survey in Switzerland. <i>Comprehensive Psychiatry</i> , 2021, 109, 152260.	1.5	27
17	Polygenic risk scores across the extended psychosis spectrum. <i>Translational Psychiatry</i> , 2021, 11, 600.	2.4	11
18	P.0006 BDNF levels in blood serum and plasma of MDMA users and MDMA-naïve controls. <i>European Neuropsychopharmacology</i> , 2021, 53, S4-S5.	0.3	0

#	ARTICLE	IF	CITATIONS
19	P.0025 Preliminary results of growth rate profiling of induced pluripotent stem cells and neuronal progenitor cells from Attention-Deficit Hyperactivity Disorder. <i>European Neuropsychopharmacology</i> , 2021, 53, S19-S20.	0.3	0
20	Genetics of obsessive-compulsive disorder and Tourette disorder. , 2020, , 239-252.		1
21	Epigenetic mechanisms in schizophrenia and other psychotic disorders: a systematic review of empirical human findings. <i>Molecular Psychiatry</i> , 2020, 25, 1718-1748.	4.1	97
22	High-resolution chromosomal microarray analysis for copy-number variations in high-functioning autism reveals large aberration typical for intellectual disability. <i>Journal of Neural Transmission</i> , 2020, 127, 81-94.	1.4	5
23	Psychiatric symptoms and expression of glucocorticoid receptor gene in cocaine users: A longitudinal study. <i>Journal of Psychiatric Research</i> , 2020, 121, 126-134.	1.5	5
24	Rare copy number variants in individuals at clinical high risk for psychosis: Enrichment of synaptic/brain-related functional pathways. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2020, 183, 140-151.	1.1	0
25	The stress-Wnt-signaling axis: a hypothesis for attention-deficit hyperactivity disorder and therapy approaches. <i>Translational Psychiatry</i> , 2020, 10, 315.	2.4	20
26	Preventing problematic internet use during the COVID-19 pandemic: Consensus guidance. <i>Comprehensive Psychiatry</i> , 2020, 100, 152180.	1.5	522
27	Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders. <i>International Clinical Psychopharmacology</i> , 2020, 35, 173-193.	0.9	70
28	ADHD: Current Concepts and Treatments in Children and Adolescents. <i>Neuropediatrics</i> , 2020, 51, 315-335.	0.3	117
29	Profiling parvalbumin interneurons using iPSC: challenges and perspectives for Autism Spectrum Disorder (ASD). <i>Molecular Autism</i> , 2020, 11, 10.	2.6	10
30	Glucocorticoid receptor gene variants and lower expression of <i>NR3C1</i> are associated with cocaine use. <i>Addiction Biology</i> , 2019, 24, 730-742.	1.4	23
31	No Association of Variants of the NPY-System With Obsessive-Compulsive Disorder in Children and Adolescents. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 112.	1.4	1
32	Guidelines for the standardized collection of blood-based biomarkers in psychiatry: Steps for laboratory validity – a consensus of the Biomarkers Task Force from the WFSBP. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 340-351.	1.3	20
33	Association study and a systematic meta-analysis of the VNTR polymorphism in the 3'-UTR of dopamine transporter gene and attention-deficit hyperactivity disorder. <i>Journal of Neural Transmission</i> , 2019, 126, 517-529.	1.4	24
34	Influence of oxytocin receptor single nucleotide sequence variants on contractility of human myometrium: an in vitro functional study. <i>BMC Medical Genetics</i> , 2019, 20, 178.	2.1	12
35	New insights and perspectives on the genetics of obsessive-compulsive disorder. <i>Psychiatric Genetics</i> , 2019, 29, 142-151.	0.6	16
36	Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. <i>Cell</i> , 2019, 179, 1469-1482.e11.	13.5	935

#	ARTICLE	IF	CITATIONS
37	Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice. <i>Neuropharmacology</i> , 2019, 148, 50-67.	2.0	17
38	Astrocyte- and Microglia-Specific Mitochondrial DNA Deletions Levels in Sporadic Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 149-157.	1.2	12
39	The involvement of the canonical Wnt signaling receptor <i>LRP5</i> and <i>LRP6</i> gene variants with ADHD and sexual dimorphism: Association study and meta-analysis. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2019, 180, 365-376.	1.1	16
40	Methylphenidate enhances neuronal differentiation and reduces proliferation concomitant to activation of Wnt signal transduction pathways. <i>Translational Psychiatry</i> , 2018, 8, 51.	2.4	21
41	Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson's Disease Substantia Nigra. <i>Neurotoxicity Research</i> , 2018, 33, 560-568.	1.3	31
42	Emerging role of miRNA in attention deficit hyperactivity disorder: a systematic review. <i>ADHD Attention Deficit and Hyperactivity Disorders</i> , 2018, 10, 49-63.	1.7	39
43	Combining genetic and epigenetic parameters of the serotonin transporter gene in obsessive-compulsive disorder. <i>Journal of Psychiatric Research</i> , 2018, 96, 209-217.	1.5	43
44	Effects of oxytocin and arginine vasopressin on the proliferation and differentiation of a serotonergic cell line. <i>Journal of Neural Transmission</i> , 2018, 125, 103-106.	1.4	2
45	Explorative results from multistep screening for potential genetic risk loci of Alzheimer's disease in the longitudinal VITA study cohort. <i>Journal of Neural Transmission</i> , 2018, 125, 77-87.	1.4	8
46	Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis. <i>Molecular Psychiatry</i> , 2018, 23, 1181-1188.	4.1	400
47	Manifesto for a European research network into Problematic Usage of the Internet. <i>European Neuropsychopharmacology</i> , 2018, 28, 1232-1246.	0.3	216
48	Improved Generation of Induced Pluripotent Stem Cells From Hair Derived Keratinocytes – A Tool to Study Neurodevelopmental Disorders as ADHD. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 321.	1.8	22
49	Neurochemical markers as potential indicators of postmortem tissue quality. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 150, 119-127.	1.0	4
50	Neuregulin 1 (NRG1) gene expression predicts functional outcomes in individuals at clinical high-risk for psychosis. <i>Psychiatry Research</i> , 2018, 266, 143-146.	1.7	4
51	A systematic meta-analysis of the association of Neuregulin 1 (NRG1), d-amino acid oxidase (DAO), and DAO activator (DAOA)/G72 polymorphisms with schizophrenia. <i>Journal of Neural Transmission</i> , 2018, 125, 89-102.	1.4	21
52	± _{2A} Adrenergic receptor polymorphisms and mRNA expression levels are associated with delay discounting in cocaine users. <i>Addiction Biology</i> , 2017, 22, 561-569.	1.4	14
53	Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2017, 124, 745-748.	1.4	8
54	The hallucinogen 2,5-dimethoxy-4-iodoamphetamine hydrochloride activates neurotrophin receptors in a neuronal cell line and promotes neurites extension. <i>Journal of Neural Transmission</i> , 2017, 124, 749-759.	1.4	8

#	ARTICLE	IF	CITATIONS
55	Integrating evolutionary and regulatory information with a multispecies approach implicates genes and pathways in obsessive-compulsive disorder. <i>Nature Communications</i> , 2017, 8, 774.	5.8	52
56	The impact of methylphenidate and its enantiomers on dopamine synthesis and metabolism in vitro. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 79, 281-288.	2.5	12
57	The diabetic brain and cognition. <i>Journal of Neural Transmission</i> , 2017, 124, 1431-1454.	1.4	77
58	Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2017, 40, 208-211.	0.2	20
59	DNA methylation profiles of elderly individuals subjected to indentured childhood labor and trauma. <i>BMC Medical Genetics</i> , 2017, 18, 21.	2.1	27
60	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 330-356.	1.3	33
61	Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 162-214.	1.3	226
62	A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy Subjects. <i>Frontiers in Pharmacology</i> , 2017, 8, 423.	1.6	11
63	Prediction Analysis for Transition to Schizophrenia in Individuals at Clinical High Risk for Psychosis: The Relationship of DAO, DAOA, and NRG1 Variants with Negative Symptoms and Cognitive Deficits. <i>Frontiers in Psychiatry</i> , 2017, 8, 292.	1.3	16
64	Expression of D-Amino Acid Oxidase (DAO/DAAO) and D-Amino Acid Oxidase Activator (DAOA/G72) during Development and Aging in the Human Post-mortem Brain. <i>Frontiers in Neuroanatomy</i> , 2017, 11, 31.	0.9	31
65	Controversial Effects of D-Amino Acid Oxidase Activator (DAOA)/G72 on D-Amino Acid Oxidase (DAO) Activity in Human Neuronal, Astrocyte and Kidney Cell Lines: The N-methyl D-aspartate (NMDA) Receptor Hypofunction Point of View. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 342.	1.4	10
66	High resolution chromosomal microarray analysis in paediatric obsessive-compulsive disorder. <i>BMC Medical Genomics</i> , 2017, 10, 68.	0.7	21
67	A pilot investigation on DNA methylation modifications associated with complex posttraumatic symptoms in elderly traumatized in childhood. <i>BMC Research Notes</i> , 2017, 10, 752.	0.6	7
68	Aldehyde dehydrogenase (ALDH) in Alzheimer's and Parkinson's disease. <i>Journal of Neural Transmission</i> , 2016, 123, 83-90.	1.4	66
69	Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: Neuroimaging and genetics. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 321-365.	1.3	118
70	CNTNAP2 gene in high functioning autism: no association according to family and meta-analysis approaches. <i>Journal of Neural Transmission</i> , 2016, 123, 353-363.	1.4	16
71	Serotonin Transporter and Tryptophan Hydroxylase Gene Variations Mediate Working Memory Deficits of Cocaine Users. <i>Neuropsychopharmacology</i> , 2015, 40, 2929-2937.	2.8	16
72	Cross-Disorder Genome-Wide Analyses Suggest a Complex Genetic Relationship Between Tourette Syndrome and OCD. <i>American Journal of Psychiatry</i> , 2015, 172, 82-93.	4.0	117

#	ARTICLE	IF	CITATIONS
73	Nine-month follow-up of the insulin receptor signalling cascade in the brain of streptozotocin rat model of sporadic Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2015, 122, 565-576.	1.4	41
74	Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimer's disease progression: CX3CL1, TREM2, and PPAR β . <i>Journal of Neural Transmission</i> , 2015, 122, 1069-1076.	1.4	43
75	Neurotrophin blood-based gene expression and social cognition analysis in patients with autism spectrum disorder. <i>Neurogenetics</i> , 2015, 16, 123-131.	0.7	35
76	Region-specific regulation of the serotonin 2A receptor expression in development and ageing in post mortem human brain. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 520-532.	1.8	11
77	Characterization of cognitive deficits in spontaneously hypertensive rats, accompanied by brain insulin receptor dysfunction. <i>Journal of Molecular Psychiatry</i> , 2015, 3, 6.	2.0	23
78	Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study. <i>Journal of Neural Transmission</i> , 2015, 122, 1055-1068.	1.4	126
79	Extraordinarily Fast Response to Low-Dose Sertraline in a Child with Severe Obsessive-Compulsive Disorder and High Functioning Serotonin Transporter Genotype. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2014, 24, 102-104.	0.7	4
80	Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene. <i>Molecular Autism</i> , 2014, 5, 43.	2.6	59
81	Imaging genetics in obsessive-compulsive disorder: Linking genetic variations to alterations in neuroimaging. <i>Progress in Neurobiology</i> , 2014, 121, 114-124.	2.8	34
82	Altered peripheral BDNF mRNA expression and BDNF protein concentrations in blood of children and adolescents with autism spectrum disorder. <i>Journal of Neural Transmission</i> , 2014, 121, 1117-1128.	1.4	47
83	Association study in siblings and case-controls of serotonin- and oxytocin-related genes with high functioning autism. <i>Journal of Molecular Psychiatry</i> , 2014, 2, 1.	2.0	39
84	Investigation of association of serotonin transporter and monoamine oxidase-A genes with Alzheimer's disease and depression in the VITA study cohort: A 90-month longitudinal study. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2014, 165, 184-191.	1.1	12
85	Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity. <i>Journal of Neural Transmission</i> , 2014, 121, 379-383.	1.4	29
86	P.1.g.071 Interaction between serotonin 1A and 2A receptor subtypes in neuronal and lymphoblastoid cells. <i>European Neuropsychopharmacology</i> , 2014, 24, S244-S245.	0.3	0
87	Copy Number Variation in Obsessive-Compulsive Disorder and Tourette Syndrome: A Cross-Disorder Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 910-919.	0.3	111
88	Trio study and meta-analysis support the association of genetic variation at the serotonin transporter with early-onset obsessive-compulsive disorder. <i>Neuroscience Letters</i> , 2014, 580, 100-103.	1.0	39
89	The neurobiological link between OCD and ADHD. <i>ADHD Attention Deficit and Hyperactivity Disorders</i> , 2014, 6, 175-202.	1.7	73
90	Prenatal stress increases the striatal and hippocampal expression of correlating c-FOS and serotonin transporters in murine offspring. <i>International Journal of Developmental Neuroscience</i> , 2014, 38, 30-35.	0.7	22

#	ARTICLE	IF	CITATIONS
91	Aldehyde dehydrogenase 2 in sporadic Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, S68-S72.	1.1	26
92	Enhancement of cell viability after treatment with polyunsaturated fatty acids. <i>Neuroscience Letters</i> , 2014, 559, 56-60.	1.0	10
93	Neuron-Specific Alterations in Signal Transduction Pathways associated with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 135-142.	1.2	29
94	Real-Time Impedance-based Cell Analyzer as a Tool to Delineate Molecular Pathways Involved in Neurotoxicity and Neuroprotection in a Neuronal Cell Line. <i>Journal of Visualized Experiments</i> , 2014, , e51748.	0.2	2
95	Wie biologisch sind Zwangsstörungen?. <i>Kindheit Und Entwicklung (discontinued)</i> , 2014, 23, 75-85.	0.1	5
96	Methylphenidate enhances neural stem cell differentiation. <i>Journal of Molecular Psychiatry</i> , 2013, 1, 5.	2.0	9
97	Is the treatment with psychostimulants in children and adolescents with attention deficit hyperactivity disorder harmful for the dopaminergic system?. <i>ADHD Attention Deficit and Hyperactivity Disorders</i> , 2013, 5, 71-81.	1.7	17
98	Manifesto for a European research network into obsessive-compulsive and related disorders. <i>European Neuropsychopharmacology</i> , 2013, 23, 561-568.	0.3	28
99	In vitro study methodologies to investigate genetic aspects and effects of drugs used in attention-deficit hyperactivity disorder. <i>Journal of Neural Transmission</i> , 2013, 120, 131-139.	1.4	8
100	Different effects of soluble and aggregated amyloid β 242 on gene/protein expression and enzyme activity involved in insulin and APP pathways. <i>Journal of Neural Transmission</i> , 2013, 120, 113-120.	1.4	15
101	Editorial. <i>Journal of Neural Transmission</i> , 2013, 120, 1-2.	1.4	2
102	5-HT2A serotonin receptor agonist DOI alleviates cytotoxicity in neuroblastoma cells: Role of the ERK pathway. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 44, 64-72.	2.5	16
103	Alzheimer's disease and type 2 diabetes: Two diseases, one common link?. <i>World Journal of Biological Psychiatry</i> , 2013, 14, 233-240.	1.3	16
104	The Loudness Dependence of Auditory Evoked Potentials (LDAEP) as an Indicator of Serotonergic Dysfunction in Patients with Predominant Schizophrenic Negative Symptoms. <i>PLoS ONE</i> , 2013, 8, e68650.	1.1	27
105	Neuron-Specific Mitochondrial DNA Deletion Levels in Sporadic Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2013, 10, 1041-1046.	0.7	14
106	Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe Study. <i>Acta Neuropathologica</i> , 2012, 124, 893-903.	3.9	110
107	Parkinson's disease: Molecular risk factors. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S45-S48.	1.1	14
108	1.12.1 PARKINSON'S DISEASE: MOLECULAR RISK FACTORS. <i>Parkinsonism and Related Disorders</i> , 2012, 18, S5.	1.1	0

#	ARTICLE	IF	CITATIONS
109	S.08.01 Potential biomarkers and genetic findings in ADHD. European Neuropsychopharmacology, 2012, 22, S123-S124.	0.3	0
110	S.08.03 New findings of copy number variations in OCD. European Neuropsychopharmacology, 2012, 22, S124.	0.3	0
111	Inflammatory Pathways in Parkinson's Disease; A BNE Microarray Study. Parkinson's Disease, 2012, 2012, 1-16.	0.6	51
112	A molecular signature in blood identifies early Parkinson's disease. Molecular Neurodegeneration, 2012, 7, 26.	4.4	99
113	Pilot study: potential transcription markers for adult attention-deficit hyperactivity disorder in whole blood. ADHD Attention Deficit and Hyperactivity Disorders, 2012, 4, 77-84.	1.7	7
114	Pilot study on HTR2A promoter polymorphism, rs1438G/A (rs6311) and a nearby copy number variation showed association with onset and severity in early onset obsessive-compulsive disorder. Journal of Neural Transmission, 2012, 119, 507-515.	1.4	32
115	Altered mRNA expression of monoaminergic candidate genes in the blood of children with attention deficit hyperactivity disorder and autism spectrum disorder. World Journal of Biological Psychiatry, 2011, 12, 104-108.	1.3	27
116	Association of a Functional NOS1 Promoter Repeat with Alzheimer's Disease in the VITA Cohort. Journal of Alzheimer's Disease, 2011, 23, 327-333.	1.2	16
117	Genetic variation in the choline O-acetyltransferase gene in depression and Alzheimer's disease: The VITA and Milano studies. Journal of Psychiatric Research, 2011, 45, 1250-1256.	1.5	15
118	Methyl- and acetyltransferases are stable epigenetic markers postmortem. Cell and Tissue Banking, 2011, 12, 289-297.	0.5	12
119	The link between iron, metabolic syndrome, and Alzheimer's disease. Journal of Neural Transmission, 2011, 118, 371-379.	1.4	50
120	Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats. Journal of Neural Transmission, 2011, 118, 1717-1725.	1.4	7
121	Editorial. Journal of Neural Transmission, 2011, 118, 299-300.	1.4	3
122	Diabetes Type II: A Risk Factor for Depression-Parkinson-Alzheimer?. Neurotoxicity Research, 2011, 19, 253-265.	1.3	50
123	Disorder-specific effects of polymorphisms at opposing ends of the Insulin Degrading Enzyme gene. BMC Medical Genetics, 2011, 12, 151.	2.1	10
124	Alteration of the pro-oxidant xanthine oxidase (XO) in the thalamus and occipital cortex of patients with schizophrenia. World Journal of Biological Psychiatry, 2011, 12, 588-597.	1.3	27
125	d/l threo-methylphenidate enantiomers influence on catecholaminergic enzyme activities. Pharmacopsychiatry, 2011, 44, .	1.7	0
126	Genetics of early-onset obsessive-compulsive disorder. European Child and Adolescent Psychiatry, 2010, 19, 227-235.	2.8	329

#	ARTICLE	IF	CITATIONS
127	Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease. Journal of Neural Transmission, 2010, 117, 1387-1393.	1.4	57
128	Effects of methylphenidate: the cellular point of view. ADHD Attention Deficit and Hyperactivity Disorders, 2010, 2, 225-232.	1.7	29
129	Increased Mitochondrial Aldehydedehydrogenase in the putamen of individuals with Alzheimer's disease. Journal of Alzheimer's Disease, 2010, 19, 1295-1301.	1.2	34
130	Increased xanthine oxidase in the thalamus and putamen in depression. World Journal of Biological Psychiatry, 2010, 11, 314-320.	1.3	72
131	Can enzyme kinetics of prooxidants teach us a lesson about the treatment of Alzheimer's disease: A pilot post-mortem study. World Journal of Biological Psychiatry, 2010, 11, 677-681.	1.3	5
132	Chronic exogenous corticosterone administration generates an insulin-resistant brain state in rats. Stress, 2010, 13, 123-131.	0.8	23
133	Brain tryptophan rather than pH-value is altered as consequence of artificial postmortem interval and storage conditions. Neurochemistry International, 2010, 57, 819-822.	1.9	7
134	PGC-1 β , A Potential Therapeutic Target for Early Intervention in Parkinson's Disease. Science Translational Medicine, 2010, 2, 52ra73.	5.8	691
135	Trabalho de consenso de fora-tarefa da WFSBP sobre marcadores biolgicos das demncias: contribuio da anlise do LCR e do sangue para o diagnstico precoce e diferencial das demncias. Revista De Psiquiatria Clinica, 2009, 36, 1-16.	0.6	1
136	Modeling Sporadic Alzheimer's Disease: The Insulin Resistant Brain State Generates Multiple Long-Term Morphobiological Abnormalities Including Hyperphosphorylated Tau Protein and Amyloid- β . Journal of Alzheimer's Disease, 2009, 18, 729-750.	1.2	94
137	Genetic risk factors and markers for Alzheimer's disease and/or depression in the VITA study. Journal of Psychiatric Research, 2009, 43, 298-308.	1.5	54
138	pH measurement as quality control on human post mortem brain tissue: a study of the BrainNet Europe consortium. Neuropathology and Applied Neurobiology, 2009, 35, 329-337.	1.8	93
139	Tryptophan is a marker of human postmortem brain tissue quality. Journal of Neurochemistry, 2009, 110, 1400-1408.	2.1	13
140	Gene Expression as Peripheral Biomarkers for Sporadic Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 627-634.	1.2	57
141	Schizophrenia: From the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World Journal of Biological Psychiatry, 2009, 10, 127-155.	1.3	64
142	Stress and methylphenidate treatment, both modulate neuronal activity in an animal model for ADHD. Pharmacopsychiatry, 2009, 42, .	1.7	0
143	Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements. Journal of Neural Transmission, 2008, 115, 1385-1392.	1.4	33
144	Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. Journal of Neurochemistry, 2008, 77, 146-156.	2.1	6

#	ARTICLE	IF	CITATIONS
145	Genomic aspects of sporadic Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, S88-S91.	1.1	3
146	Altered glial cell line-derived neurotrophic factor (GDNF) concentrations in the brain of patients with depressive disorder: A comparative post-mortem study. <i>European Psychiatry</i> , 2008, 23, 413-420.	0.1	68
147	Commonalities in the genetics of Alzheimer's disease and Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1865-1877.	1.4	13
148	Genes and Oxidative Stress in Sporadic and Familial Parkinsonism: cDNA Microarray Studies. , 2007, , 201-218.		0
149	Alterations in Expression of Glutamatergic Transporters and Receptors in Sporadic Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2007, 11, 97-116.	1.2	257
150	Comparison Analysis of Gene Expression Patterns between Sporadic Alzheimer's and Parkinson's Disease. <i>Journal of Alzheimer's Disease</i> , 2007, 12, 291-311.	1.2	57
151	1.011 Early diagnosis for Parkinson's disease according to whole blood gene profile. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S30.	1.1	0
152	1.100 Early diagnosis for Parkinson's disease according to whole blood gene profile. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S33-S34.	1.1	0
153	Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. <i>Journal of Neurochemistry</i> , 2007, 101, 757-770.	2.1	321
154	Behavioural and expressional phenotyping of nitric oxide synthase-I knockdown animals. , 2007, , 69-85.		40
155	The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice. <i>Journal of Neural Transmission</i> , 2007, 114, 205-209.	1.4	27
156	Biostatistical analysis of gene microarrays reveals diverse expression clusters between macaque subspecies in brain SIV infection. , 2007, , 317-322.		0
157	Gene and Protein Expression Profiling in Parkinson's Disease: Quest for Neuroprotective Drugs. , 2007, , 61-76.		0
158	HIV Dementia: A Neurodegenerative Disorder with Viral Etiology. , 2007, , 359-371.		0
159	Methylphenidate effects on cell growth and maturation in neuronal stem cells. <i>Pharmacopsychiatry</i> , 2007, 40, .	1.7	0
160	Gene expression alterations in brain areas of intracerebroventricular streptozotocin treated rat. <i>Journal of Alzheimer's Disease</i> , 2006, 9, 261-271.	1.2	33
161	Estrogen Receptor β Gene (ESR β) 3' UTR Variants in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, 322-323.	0.6	16
162	Serotonin transporter polymorphism and LDL-cholesterol. <i>Molecular Psychiatry</i> , 2006, 11, 707-709.	4.1	24

#	ARTICLE	IF	CITATIONS
163	Microarray analysis reveals distinct gene expression patterns in the mouse cortex following chronic neuroleptic and stimulant treatment: implications for body weight changes. <i>Journal of Neural Transmission</i> , 2006, 113, 1383-1393.	1.4	23
164	Association study of BDNF and CNTF polymorphism to depression in non-demented subjects of the "VITA" study. <i>Journal of Affective Disorders</i> , 2006, 96, 111-116.	2.0	22
165	Association Study of the 5-HTTLPR Polymorphism and Depression in 75-Year-Old Nondemented Subjects From the Vienna Transdanube Aging (VITA) Study. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1373-1378.	1.1	34
166	Early impairment in dopaminergic neurotransmission in brains of SIV-infected rhesus monkeys due to microglia activation. <i>Journal of Neurochemistry</i> , 2005, 95, 377-387.	2.1	51
167	Consensus Paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia. <i>World Journal of Biological Psychiatry</i> , 2005, 6, 69-84.	1.3	105
168	Oxidative stress related markers in the "VITA" and the centenarian projects. <i>Neurobiology of Aging</i> , 2005, 26, 429-438.	1.5	34
169	Gene Expression Profiling of Sporadic Parkinson's Disease Substantia Nigra Pars Compacta Reveals Impairment of Ubiquitin-Proteasome Subunits, SKP1A, Aldehyde Dehydrogenase, and Chaperone HSC70. <i>Annals of the New York Academy of Sciences</i> , 2005, 1053, 356-375.	1.8	2
170	Gene Expression Profiling of Sporadic Parkinson's Disease Substantia Nigra Pars Compacta Reveals Impairment of Ubiquitin-Proteasome Subunits, SKP1A, Aldehyde Dehydrogenase, and Chaperone HSC-70. <i>Annals of the New York Academy of Sciences</i> , 2005, 1053, 356-375.	1.8	136
171	Gene expression profile in streptozotocin rat model for sporadic Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2004, 111, 367-386.	1.4	48
172	Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. <i>Journal of Neural Transmission</i> , 2004, 111, 1543-1573.	1.4	326
173	Monoamine Oxidase-B Inhibition in Alzheimer's Disease. <i>NeuroToxicology</i> , 2004, 25, 271-277.	1.4	221
174	The benefits of microarrays as tools for studying neuropsychiatric disorders. <i>Drugs of Today</i> , 2004, 40, 147.	2.4	10
175	The benefits of microarrays as tools for studying neuropsychiatric disorders. <i>Drugs of Today</i> , 2004, 40, 147-56.	0.7	5
176	Neuroprotective Strategies in Parkinson's Disease. <i>CNS Drugs</i> , 2003, 17, 729-762.	2.7	206
177	Genes and oxidative stress in parkinsonism: cDNA microarray studies. <i>Advances in Neurology</i> , 2003, 91, 123-32.	0.8	13
178	Preclinical versus clinical neuroprotection. <i>Advances in Neurology</i> , 2003, 91, 309-28.	0.8	0
179	Free radicals in Parkinson's disease. <i>Journal of Neurology</i> , 2002, 249, 1-1.	1.8	95
180	Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. <i>Neurochemical Research</i> , 2002, 27, 1231-1243.	1.6	58

#	ARTICLE	IF	CITATIONS
181	Early and late molecular events in neurodegeneration and neuroprotection in Parkinson's disease MPTP model as assessed by cDNA microarray; the role of iron. Neurotoxicity Research, 2002, 4, 679-689.	1.3	33
182	Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. Journal of Neurochemistry, 2001, 78, 1-12.	2.1	189
183	Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. Journal of Neurochemistry, 2001, 77, 146-156.	2.1	86
184	Drugs to prevent cell death in Parkinson's disease. Neuroprotection against oxidative stress and inflammatory gene expression. Advances in Neurology, 2001, 86, 115-24.	0.8	7
185	Neuroprotective Strategies in Parkinson's Disease Using the Models of 6-Hydroxydopamine and MPTP. Annals of the New York Academy of Sciences, 2000, 899, 262-273.	1.8	78
186	Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine. , 2000, , 83-96.		14
187	cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease. , 2000, , 117-124.		32
188	MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies. Journal of Neurology, 2000, 247, 1195-11102.	1.8	78
189	Contribution of Intracellular Non-Haem Iron, NF-kB Activation and Inflammatory Responses to Neurodegeneration in Parkinson's Disease: Prospects for Neuroprotection. , 2000, , 277-288.		0
190	The Pivotal Role of Iron in NF-kappaB Activation and Nigrostriatal Dopaminergic Neurodegeneration: Prospects for Neuroprotection in Parkinson's Disease with Iron Chelators. Annals of the New York Academy of Sciences, 1999, 890, 7-25.	1.8	81
191	Apomorphine protects against MPTP-induced neurotoxicity in mice. Movement Disorders, 1999, 14, 612-618.	2.2	114
192	Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity. , 1999, 55, 57-70.		25
193	Increased xanthine oxidase in the thalamus and putamen in depression. World Journal of Biological Psychiatry, 0, , 1-7.	1.3	15